Novel biomarkers in Alzheimer's disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolites.
Alzheimer's disease (AD) is the most common form of dementia. It affects approximately 6% of people over the age of 65 years. It is a clinicopathological, degenerative, chronical and progressive disease that exhibits a deterioration of memory, orientation, speech and other functions. Factors contrib...
| Published in: | Critical Reviews in Clinical Laboratory Sciences Vol. 58; no. 3; pp. 167 - 180 |
|---|---|
| Main Authors: | , , , |
| Format: | pictorial review tables/charts Journal Article |
| Published: |
Taylor & Francis Ltd
May2021
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150085996&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 150085996 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10408363 1AV jtl: Critical Reviews in Clinical Laboratory Sciences issn: 10408363 maglogo: Y pubinfo: dt: May2021 vid: 58 iid: 3 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 150085996 146777600 150085996 150085996 10.1080/10408363.2020.1833298 150085996 ppf: 167 ppct: 13 formats: fmt: @attributes: type: P tig: atl: Novel biomarkers in Alzheimer's disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolites. aug: au: Navas-Carrillo, Diana Rivera-Caravaca, José Miguel Sampedro-Andrada, Arturo Orenes-Piñero, Esteban affil: Department of Surgery, Hospital HLA La Vega, Murcia, Spain sug: subj: Biological Markers Alzheimer's Disease Diagnosis Proteomics Metabolomics MicroRNA Proteins Metabolites Amyloid beta-Peptides tau Proteins Alzheimer's Disease Physiopathology Alzheimer's Disease Prevention and Control Alzheimer's Disease Familial and Genetic ab: Alzheimer's disease (AD) is the most common form of dementia. It affects approximately 6% of people over the age of 65 years. It is a clinicopathological, degenerative, chronical and progressive disease that exhibits a deterioration of memory, orientation, speech and other functions. Factors contributing to the pathogenesis of the disease are the presence of extracellular amyloid deposits, called neuritic senile plaques, and fibrillary protein deposits inside neurons, known as neurofibrillary bundles, that appear mainly in the frontal and temporal lobes. AD has a long preclinical latency and is difficult to diagnose and prevent at early stages. Despite the advent of novel high-throughput technologies, it is a great challenge to identify precise biomarkers to understand the progression of the disease and the development of new treatments. In this sense, important knowledge is emerging regarding novel molecular and biological candidates with diagnostic potential, including microRNAs that have a key role in gene repression. On the other hand, proteomic approaches offer a platform for the comprehensive analysis of the whole proteome in a certain physiological time. Proteomic technology investigates protein expression directly and reveals post-translational modifications known to be determinant for many human diseases. Clinically, there is growing evidence for the role of proteomic and metabolomic technologies in AD biomarker discovery. This review discusses the role of several miRNAs identified using genomic technologies, and the importance of novel proteomic and metabolomic approaches to identify new proteins and metabolites that may be useful as biomarkers for monitoring the progression and treatment of AD. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|